Registration Dossier

Administrative data

Description of key information

The acute dermal and oral toxicity of the test substance MBS is very low, indicated by LD50 values greater than 5000 mg/kg. The acute oral LD50 value in rats is greater than 7940 mg/kg (Monsanto 1973) and the dermal LD50 value in rabbits is greater than 7940 mg/kg bw (Monsanto 1973). 

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Dose descriptor:
LD50
7 940 mg/kg bw

Acute toxicity: via dermal route

Endpoint conclusion
Dose descriptor:
LD50
7 940 mg/kg bw

Additional information

Acute toxicity: oral

The test substance MBS was evaluated in an acute oral toxicity study with male and female Sprague-Dawley Albino rats. A 25% suspension of the test substance in corn oil was administered by gavage to male and female rats at doses of 5010, 6310 and 7940 mg/kg bw. A 7-day observation period followed administration. The oral LD50 was greater than 7940 mg/kg bw. Mortality occurred at the highest dose group. The number of deaths was 1 out of 5 animals. Clinical signs were observed and included reduced appetite and activity (one to three days in survivors), increasing weakness, collapse and death. Autopsy of decedent showed hemorrhagic lungs and liver and acute gastrointestinal inflammation; viscera of surviving animals appeared normal at sacrifice (Monsanto Co. 1973).

The very low toxicity of MBS was confirmed by further acute toxicity studies with rats indicated by LD50 values higher than 5000 mg/kg bw (Bayer AG 1978) or even higher than 10000 mg/kg bw (de Groot 1976).

Acute toxicity: dermal

The acute dermal toxicity of the test substance MBS was evaluated in an acute dermal toxicity study with New Zealand albino rabbits (Monsanto 1973). A 40 % suspension of the test substance in corn oil was applied for 24 hours directly to the skin of 4 (2 males and 2 females) New Zealand albino rabbits at doses of 3160, 5010 and 7940 mg/kg bw. No mortality occurred. The dermal LD50 for the test substance MBS was greater than 7940 mg/kg bw. Clinical signs were observed and included reduced appetite and activity for one to three days.

Justification for classification or non-classification

No classification is required according to the classification criteria 67/548/EWG and regulation no. 1272/2008 (GHS).